Belzutifan plus lenvatinib advances second-line ccRCC treatment
Phase III LITESPARK-011 showed belzutifan plus lenvatinib improved outcomes versus cabozantinib in previously treated advanced clear-cell renal cell carcinoma.
This section contains the website’s posts.